AIDS-Related malignancies: Revisited

Puerto Rico Health Sciences Journal

Volumn 29, Issue 1, 2010, Pages 70-75

  Cáceres, William ^a   Cruz Amy, Marinely ^b   Díaz Meléndez, Vivian ^b  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b Fellow Hematology Oncology San Juan City Hospital program   (United States)

Author keywords

Acquired immunodeficiency disease; Kaposi's sarcoma; Non hodgkin's lymphoma; Protease inhibitors

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; B CELL LYMPHOMA; HUMAN; NEOPLASM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMANS; LYMPHOMA, AIDS-RELATED; NEOPLASMS;

EID: 77349101588     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. CDC. MMWR. Surveillance summaries for AIDS-defining opportunistic diseases, 1992-1997. Atlanta: Centers for Disease Control and Prevention, 1999: p. 1.
2. Spano JD, Costagliola D, Katlama C, et al. AIDS-related malignancies: state of the art and therapeutic challenges. JClin Oncol 2008;26:4834-4842.
3. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-1654.
4. Lewden C, May T, Rosenthal E, et al. Causes of death among HIV-infected adults in France in 2005 and evolution since 2000. Bull Epidemiol Hebdomadaire 2006;48:379-382.
5. Biggar RJ, Engels EA, Ly S, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005;39:293-299.
6. Pantanowitz L, Schlecht HP, Dezube BJ. The growing problem of non-AIDS- defining malignancies in HIV. Curr Opin Oncol 2006;18: 469-478.
7. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Immunodeficiency and risk of AIDS-defining and non-AIDS defining cancers: ANRS CO3 Aquitaine Cohort, 1998 to 2006. 15th Conference on Retroviruses and Opportunistic Infections, Boston MA, 3-6 February 2008 (abstr 15).
8. Ambinder RF. HIV-associated malignancies in Abeloff MD, Armitage JO, Niederhube JE, Kastan MD, McKenna WG, eds. Clinical Oncology, 3rd edition, Elsevier Inc., 2004: p. 2648-2652.
9. Chang Y, Cesarman E, Pessin MS, et al. Identification of herperviruslike DNA sequence in AIDS associated Kaposi's sarcoma. Science 1994; 266:1865-1869.
10. Schwartz EJ, Dorfman RF, Kohler S. Human herpesvirus-8 latent nuclear antigen -1 expression in endemic Kaposi sarcoma: An immunohistochemical study of 16 cases. Am J Surg Pathol 2003;27:1546-1550.
11. Yarchoan R. Key role for a viral lytic gene in Kaposi's sarcoma. NEngl JMed 2006;355:1383-1385.
12. Grisotto MG, Garin A, Martin AP, et al. The human herpesvirus 8 cytokine receptor vGPCR triggers autonomous pro;liferation of endothelial cells, J Clin Invest 2006;116:1264-1273.
13. Bais C, Santomasso B, Coso O, et al. Gprotein coupled receptor of Kaposi's sarcoma -associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998;391:86-89.
14. Sodhi A, Montaner S, Gutkind JS. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis? FASEB J 2004; 18:422-427.
15. Cheung MC, Pantanowitz L, Dezube BJ. AIDS -related malignancies: Emerging challenges in the era of highly active retroviral therapy. Oncologist 2005;10:412-426.
16. Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, et al. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol 2007;8:167-176.
17. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcomaInternational Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998;16:683-691.
18. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal doxorubicin versus bleomycin and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14:2353-2364.
19. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS- related Kaposi's sarcoma. J Clin Oncol 1999;17:1876-1883.
20. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998;16:1112-1121.
21. Lim ST, Tupule A, Espina BM, Levine AM. Weekly docetaxel is safe and effective in the treatment of advanced -stage acquired immunodeficiency syndrome-related Kaposi's sarcoma. Cancer 2005;103:417-421.
22. May T, Lewden C, Bonnet F, et al. Causes and characteristics of death among HIV-1 infected patients with immunovirologic response to antiretroviral treatment. Presse Med 2004;33:1487-1492.
23. Mbulaiteye SM, et al. Immunedeficiency and risk of malignancy among persons with AIDS. J Acquired Immuno Defic Syndrome 2003;32:527.
24. Cesarman E, et al. Kaposi's sarcoma associated herpesvirus-like DNA sequences in AIDS: related body cavity lymphomas. NEngl J Med 1995;332:1186.
25. Karcher DS, Alkan S. Human herpesvirus-8-associated body cavity- based lymphoma in human-immunodeficiency virus-infected patients. A unique B-cell neoplasm. Human Pathol 1997;28:801.
26. Scadden DT. AIDS-related lymphomas in Hoffman R, Benz EJ, Furie B, et al; eds. Hematology, 4th edition; Elsevier 2005;1490-1493.
27. Jones D. Brief report: primary effusion lymphoma and Kaposi's sarcoma in a cardiac transplant recipient. N Eng J Med 1998;339:444-449.
28. Simonelli C, Spina M, Cinelli R, Talamini R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single -institution study. J Clin Oncol 2003;21:3948-3954.
29. Cáceres W. Non-Hodgkin's lymphomas with the acquired immunodeficiency syndrome. Bol Asoc Med P R 1995;87:158-161.
30. Mounier N, Spina M, Gisselbrecht C. Modern management of nonHodgkin's lymphoma in HIV-infected patients. Br J Haematol 2007;136: 685-698.
31. Kirk O, Pedersen C, Cossi-lepri A, et al. Non-Hodgkin's lymphoma in HIV-infected patients in the era of highly active antirretroviral therapy. Blood 2001;98:2406-3412.
32. Hoffmann C, Wolf E, Faetkenheuer G. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS related lymphoma. AIDS 2003;17:1521-1529
33. Vaccher E, Spina M, di Gennaro G. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 2001;91:155-163.
34. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma: AIDS Malignancies Consortium Trial 010. Blood 2005;106:1538-1543.
35. Boué F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-4128.
36. Krishman A, Molina A, Forman SJ. Organ transplantation in HIV-infected patients. N Engl J Med 2002;347:1801-1803.
37. Levine AM. Stem cell transplantation in AIDS-lymphoma. Blood 2009; 114:1284-1285.
38. Hutter G, Scheiden T, Thiel E. Transplantation of selected or transgenic blood stem cells, a future treatment for HIV/AIDS? J Intl AIDS Soc 2009; 28:12:10.
39. Heard I, Foulot H, Potard V, Costagliola D, Chapron C. Cervical cancer in HIV-positive women. 23rd International Papillomavirus Conference, September 1-7, 2006, Prague, Czech republic.
40. Heard I, Palefsky JM, Karatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antiviral Therapy 2004;9:13-22.
41. Spina M, Berreta M, Tirelli U. Hodgkin's disease in HIV. Hematol Oncol Clin North Am 2003;17:843-858.
42. Vaccher E, Spina M, Tirelli U. Clinical aspects and management of Hodgkin's disease and other tumors in HIV-infected individuals. Eur J Cancer 2001;37:1306-1315.
43. Levine AM. Hodgkin lymphoma: to the HAART of the matter. Blood 2006;108:3630.
44. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Hematol 2004;125:455-462.
45. Abramowitz L, Ravaud P, et al. Anal squamous intraepithelial lesions and condyloma in HIV infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS 2007;21:1457-1466.
46. Roelofsen F, Bosset JF, et al. Concomitant radiotherapy and chemotherapy superior to radiotherapy alone in the treatment of locally advanced anal cancer. Proc Am Soc Clin Oncol 1995;14:194-199.
47. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual men and bisexual HIV men. JAMA 1999;281:1822-1829.
48. Spano JP, Massiani MA, Bentata M, et al. Lung cancer in patients with HIV infection and review of the literature. Med Oncol 2004;21:109-115.
49. Cadranel J, Garfield D, Lavole A, et al. Lung cancer in HIV patients;facts, questions and challenges. Thorax 2006;61:1000-1008.
50. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol 2007;3:583-598.
51. Parameswaran R, Sweeney C, Einhorn LH. Interaction between highly active antiretroviral therapy (HAART) and taxanes: a report of wo cases. Proc Am Soc Clin Oncol 2002;21:95b.